HVO.LSE hVIVO plc
- Market cap
- GBX 37.7M
- P/E
- -
- P/B
- 1.21x
- ROE
- -80.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is HVO.LSE undervalued?
Graham numberThe Graham number of hVIVO plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
hVIVO plc fundamental analysis
No fundamental analysis for hVIVO plc yet.
hVIVO plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About hVIVO plc
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immuno…
Full company profilehVIVO plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
hVIVO plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.3M | 15.5M | 12.5M | 3.28M | 20.6M | 36.9M | 48.5M | 56.0M | 62.7M | 46.8M | 65.1M |
| Gross Profit | 15.3M | 15.5M | 12.5M | -4.78M | 19.9M | 35.9M | 4.00M | 10.4M | 62.7M | -6.12M | 4.86M |
| Operating Income | -478K | 46.2K | -2.13M | -4.99M | -10.4M | 590K | 6.02M | 10.1M | 12.9M | -349K | -34.0M |
| EBITDA | -77.6K | -806K | -3.67M | -4.83M | -8.55M | 3.07M | 2.70M | 14.0M | 17.8M | 4.31M | -24.2M |
| Net Income | 453K | -1.37M | -4.30M | -5.59M | -10.8M | -74.0K | -776K | 16.1M | 10.7M | -5.99M | -25.8M |
| EPS | 0.01 | -0.02 | -0.06 | -0.03 | -0.02 | 0.00 | 0.00 | 0.02 | 0.02 | -0.01 | -0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 12.5M | 10.8M | 7.81M | 9.08M | 48.5M | 42.3M | 51.4M | 83.2M | 88.9M | 71.8M | 73.1M |
| Total Liabilities | 3.65M | 3.07M | 3.88M | 6.22M | 26.2M | 21.6M | 31.2M | 48.9M | 44.2M | 33.7M | 41.0M |
| Shareholders' Equity | 8.89M | 7.77M | 3.93M | 2.86M | 22.3M | 20.7M | 20.2M | 34.3M | 44.7M | 38.2M | 32.1M |
| Cash & Short-term Investments | 2.90M | 1.04M | 990K | 1.04M | 19.2M | 15.7M | 28.4M | 37.0M | 44.2M | 14.3M | 13.0M |
| Total Debt | 51.1K | 22.2K | 1.41M | 3.14M | 4.80M | 3.15M | 2.30M | 12.5M | 12.9M | 14.8M | 13.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -293K | -1.17M | -996K | -2.78M | 4.17M | -1.56M | 16.0M | 17.2M | 10.3M | -13.4M | 2.00M |
| Capital Expenditure | 0.00 | 486K | 71.2K | 23.1K | 1.09M | 739K | 1.36M | 5.18M | 2.46M | 1.40M | 304K |
| Free Cash Flow | -293K | -1.66M | -1.07M | -2.80M | 3.08M | -2.30M | 14.6M | 12.1M | 7.88M | -14.8M | 1.70M |
| Ratios | |||||||||||
| ROE | 5.1% | -17.6% | -109.5% | -195.3% | -48.4% | -0.4% | -3.8% | 46.9% | 23.8% | -15.7% | -80.5% |
| ROA | 3.6% | -12.6% | -55.2% | -61.6% | -22.2% | -0.2% | -1.5% | 19.4% | 12.0% | -8.3% | -35.3% |
| Net Profit Margin | 3.0% | -8.8% | -34.3% | -170.2% | -52.4% | -0.2% | -1.6% | 28.8% | 17.0% | -12.8% | -39.7% |
| Debt to Equity | 0.01x | 0.00x | 0.36x | 1.10x | 0.22x | 0.15x | 0.11x | 0.37x | 0.29x | 0.39x | 0.43x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
hVIVO plc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 15, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 1.37M | 0.00 | - |
| 2024 | GBP 1.36M | 0.00 | 12.7% |
| 2023 | GBP 3.05M | 0.00 | 19.0% |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:30 on Dec 14, 2012.
Who owns hVIVO plc
- Insiders 3.11%
- Institutions 30.63%
- Public & others 66.26%
- Shares outstanding 688M
- Free float 565M
hVIVO plc company profile
- Company name
- hVIVO plc
- Ticker
- HVO.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 376
- Fiscal year end
- December
- Address
- 40 Bank Street, London, United Kingdom, E14 5NR
- Phone
- 44 20 7756 1300
- Website
- hvivo.com
About hVIVO plc
hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides preclinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company also provides clinical research services, including early-phase trials and human pharmacological studies. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.
hVIVO plc management
10- Dr. Yamin Mohammed Khan Ph.D.CEO & Director · born 1969
- Mr. Richard John Cotton BA Hons, FCMAInterim CFO & Director · born 1961
- Mr. Andrew CatchpoleChief Scientific Officer
- Susan StuartHead of IR & Corporate Communications
- Ms. Teja Marathe-SarvadikarHead of Quality Assurance
- Dr. Thomas Forst M.D.Chief Medical Officer
- Mr. Erik GoutHead of CMC
- Mr. Chris ForsdykeHead of Laboratory Services
- Dr. Sara ArmaniHead of Medical Affairs
- Ms. Isabelle AckermannHead of Data Management